Physician profile
Thomas D Blue
NPI 1548258767
$1,151.71
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.85 · 2020: $135 · 2021: $449 · 2022: $219 · 2023: $31.60 · 2024: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Entertainment: $245 · Food and Beverage: $65.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Entertainment | $245.07 |
| Food and Beverage | $65.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $354.07 | 2019-2022 | |
| Optos, INC. | $245.07 | 2023-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Allergan, INC. | $159.92 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $105.14 | 2021 | |
| Biotissue Holdings INC. | $88.78 | 2021-2024 | |
| Bausch & Lomb Americas INC. | $65.70 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $59.48 | 2021 | |
| Sun Pharmaceutical Industries INC. | $27.84 | 2021-2022 | |
| Abb Con-Cise Optical Group LLC | $20.45 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.04 | 2020 | |
| Shire North American Group INC | $11.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Blue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.